Phase III Clinical Trial of the Innovative Drug-Antimicrobial Peptide PL-5 Spray Was Launched
On August 19, 2021, the “National Conference of Researchers on Phase III Clinical Trial of antimicrobial peptide PL-5 Spray in the treatment of secondary wound infection” was successfully held, marking that the clinical trial of the National “12th Five-Year Plan” and “13th Five-Year Plan” Mega-Projects for Innovative Drugs of China and the national category I innovative drug PL-5 officially will enter the home-stretch phase.
The conference was carried out in the mode of online communication due to the COVID-19 pandemic. The phase III clinical trial is led by Professor Wu Jun, from First Affiliated Hospital of Shenzhen University, 41 clinical centers jointly participate in the trial in China. Professor Wu Jun, chief principal investigator of the project, former chairman of the Burn Surgery Branch of the Chinese Medical Association, and the director of the Burn Orthopedics Department of the First Affiliated Hospital of Shenzhen University delivered a welcome speech. Professor Chen Yuxin, founder, chairman and CEO of ProteLight Pharma, directors of Guangzhou Huayin Medical Research Institute and CRO company Tigermed delivered speeches at the conference, respectively. delivered speeches at the conference, respectively. Professor Chen introduced the development of ProteLight Pharma, project information, and the mechanism and information of antimicrobial peptide PL-5 spray to participating experts. Antimicrobial peptide PL-5 spray has the advantages of high efficiency, broad-spectrum, low toxicity and not being prone to drug resistance, and is the new generation of broad-spectrum anti-infective drugs.
Professor Wu Jun of Shenzhen Second People's Hospital delivered an opening speech Shenzhen Second People's Hospital offline meeting site
Guangzhou Red Cross Hospital offline meeting site The scene of the offline meeting of the First Affiliated Hospital of Wenzhou Medical University
During the conference, Professor Wu Jun and all the participating experts had a full and passionate discussion about the Phase III clinical research plan. The participating researchers actively put forward their valuable suggestions for the flow of clinical trial operations and microbial testing assays. At the conference, ProteLight Pharma expresses its recognition and gratitude to the research teams for outstanding performance in the phase IIb clinical study of the antimicrobial peptide PL-5 spray. Professor Wu Jun announced the list of awards and winners. At the end of the conference, Professor Wu Jun summarized the discussions and made a concluding speech. The National Conference of Researchers on Phase III Clinical Trial of antimicrobial peptide PL-5 Spray was successfully ended.